Scholarlink

<p>Scanner-related changes in data quality are common in medical imaging, yet monitoring their impact on diagnostic AI performance remains challenging. In this study, we performed standardized consistency testing of an FDA-cleared and CE-marked AI for triage and notification of intracranial aneurysms across changes in image data quality caused by dose and image reconstruction. Our assessment was based on repeated examinations of a head CT phantom designed for AI evaluation, replicating a patient with three intracranial aneurysms in the anterior, middle and posterior circulation. We show that the AI maintains stable performance within the medium dose range but produces inconsistent results at reduced dose and, unexpectedly, at higher dose when filtered back projection is used. Data quality standards required for AI are stricter than those for neuroradiologists, who report higher aneurysm visibility rates and experience performance degradation only at substantially lower doses, with no decline at higher doses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inconsistency of AI in intracranial aneurysm detection with varying dose and image reconstruction

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月6日

查看全文
  • Leonie Goelz,
  • Angelo Laudani,
  • Ulrich Genske,
  • Michael Scheel,
  • Georg Bohner,
  • Hans-Christian Bauknecht,
  • Sven Mutze,
  • Bernd Hamm,
  • Paul Jahnke

摘要

Scanner-related changes in data quality are common in medical imaging, yet monitoring their impact on diagnostic AI performance remains challenging. In this study, we performed standardized consistency testing of an FDA-cleared and CE-marked AI for triage and notification of intracranial aneurysms across changes in image data quality caused by dose and image reconstruction. Our assessment was based on repeated examinations of a head CT phantom designed for AI evaluation, replicating a patient with three intracranial aneurysms in the anterior, middle and posterior circulation. We show that the AI maintains stable performance within the medium dose range but produces inconsistent results at reduced dose and, unexpectedly, at higher dose when filtered back projection is used. Data quality standards required for AI are stricter than those for neuroradiologists, who report higher aneurysm visibility rates and experience performance degradation only at substantially lower doses, with no decline at higher doses.